Literature DB >> 16322339

No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma.

M Montani1, A M Schmitt, S Schmid, T Locher, P Saremaslani, P U Heitz, P Komminoth, A Perren.   

Abstract

Germline mutations of the three succinate dehydrogenase subunits SDHB, SDHC and SDHD have recently been associated with familial pheochromocytoma and paraganglioma. Several reasons make these genes candidate tumor suppressor genes for medullary thyroid carcinoma (MTC): (1) SDHB lies on chromosome 1p, the region known to be deleted most frequently in MTC, (2) MTCs develop from neural crest-derived cells, as do pheochromocytomas and paragangliomas and (3) patients with germline mutations of the Ret-protooncogene develop MTCs as well as pheochromocytomas, indicating a relationship of these tumors on a genetic level. Therefore, we attempted to determine whether the tumor suppressor genes SDHB, SDHC and SDHD are involved in sporadic and familial MTC. Somatic mutations of the SDH subunits were absent in all 35 investigated MTCs. Loss of heterozygosity was found in 27% (SDHB) and 4% (SDHD) respectively. While the frequency of non-coding, intronic polymorphisms did not differ in MTC patients compared with a control population, an accumulation of amino-acid coding polymorphisms (S163P in SDHB as well as G12S and H50R in SDHD) was found among MTC patients especially patients with familial tumors, suggesting a functional connection of coding SDH polymorphisms to activating Ret mutations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322339     DOI: 10.1677/erc.1.00996

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  8 in total

1.  Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia.

Authors:  Enrico Saggiorato; Ida Rapa; Francesca Garino; Gianni Bussolati; Fabio Orlandi; Mauro Papotti; Marco Volante
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

Review 2.  Mitochondria and cancer.

Authors:  Valdemar Máximo; Jorge Lima; Paula Soares; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2009-04-03       Impact factor: 4.064

Review 3.  The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.

Authors:  Sosipatros A Boikos; Constantine A Stratakis
Journal:  Endocrine       Date:  2014-07-16       Impact factor: 3.633

4.  Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution.

Authors:  Katie S Murray; Emily C Zabor; Massimiliano Spaliviero; Paul Russo; Wassim M Bazzi; John E Musser; A Ari Hakimi; Melanie L Bernstein; Guido Dalbagni; Jonathan A Coleman; Helena Furberg
Journal:  World J Urol       Date:  2016-04-22       Impact factor: 4.226

5.  The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas.

Authors:  Christopher Kim; Xiaofeng Bi; Dongsheng Pan; Yingtai Chen; Tobias Carling; Shuangge Ma; Robert Udelsman; Yawei Zhang
Journal:  Thyroid       Date:  2013-04-18       Impact factor: 6.568

6.  Down-regulation of succinate dehydrogenase subunit B and up-regulation of pyruvate dehydrogenase kinase 1 predicts poor prognosis in recurrent nasopharyngeal carcinoma.

Authors:  ZhiJian Dai; Shenhua Pan; Congxi Chen; Longhe Cao; Xianhui Li; Xiaofeng Chen; Xiaoqing Su; Sen Lin
Journal:  Tumour Biol       Date:  2015-11-07

Review 7.  SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.

Authors:  B Pasini; C A Stratakis
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

8.  Over-representation of the G12S polymorphism of the SDHD gene in patients with MEN2A syndrome.

Authors:  Nikoletta Lendvai; Miklos Tóth; Zsuzsanna Valkusz; Gabriella Bekő; Nikolette Szücs; Eva Csajbók; Péter Igaz; Balázs Kriszt; Balázs Kovács; Károly Rácz; Attila Patócs
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.